BR112019008279A2 - uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1 - Google Patents
uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1Info
- Publication number
- BR112019008279A2 BR112019008279A2 BR112019008279-4A BR112019008279A BR112019008279A2 BR 112019008279 A2 BR112019008279 A2 BR 112019008279A2 BR 112019008279 A BR112019008279 A BR 112019008279A BR 112019008279 A2 BR112019008279 A2 BR 112019008279A2
- Authority
- BR
- Brazil
- Prior art keywords
- cancer
- dkk
- antibody
- biomarker
- cancer treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662413198P | 2016-10-26 | 2016-10-26 | |
| US62/413,198 | 2016-10-26 | ||
| PCT/US2017/058555 WO2018081437A1 (en) | 2016-10-26 | 2017-10-26 | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019008279A2 true BR112019008279A2 (pt) | 2019-07-09 |
Family
ID=60570180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019008279-4A BR112019008279A2 (pt) | 2016-10-26 | 2017-10-26 | uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11267876B2 (https=) |
| EP (1) | EP3532099A1 (https=) |
| JP (2) | JP7374765B2 (https=) |
| KR (1) | KR102701695B1 (https=) |
| CN (1) | CN110114087A (https=) |
| AU (1) | AU2017347822B2 (https=) |
| BR (1) | BR112019008279A2 (https=) |
| CA (1) | CA3041325A1 (https=) |
| IL (1) | IL266199B2 (https=) |
| MA (1) | MA46673A (https=) |
| MX (1) | MX2019004940A (https=) |
| RU (1) | RU2019115946A (https=) |
| SG (1) | SG11201903602RA (https=) |
| WO (1) | WO2018081437A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3041325A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CA3128526A1 (en) | 2019-02-01 | 2020-08-06 | Board Of Regents, The University Of Texas System | Monoclonal antibodies against mhc-bound human dickkopf-1 peptides and uses thereof |
| CA3151228A1 (en) * | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
| EP4061419A1 (en) * | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| WO2023143444A1 (zh) | 2022-01-28 | 2023-08-03 | 上海君实生物医药科技股份有限公司 | 抗dkk1抗体、其药物组合物及用途 |
| US20250222062A1 (en) * | 2022-03-24 | 2025-07-10 | The Translational Genomics Research Institute | Peptide inhibitors targeting the tbl1-beta-catenin complex |
| CN116350758B (zh) * | 2023-03-16 | 2024-08-06 | 郑州大学 | 肿瘤共享新抗原表位肽或其编码核酸在制备药物中的应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US7446181B2 (en) | 1998-01-15 | 2008-11-04 | Millennium Pharmaceuticals, Inc. | Antibodies that bind human Dickkopf-1 proteins |
| AR060017A1 (es) | 2006-01-13 | 2008-05-21 | Novartis Ag | Composiciones y metodos de uso para anticuerpos de dickkopf -1 |
| CA2677356A1 (en) | 2007-02-08 | 2008-08-14 | Zhiqiang An | Antibodies specific for dkk-1 |
| WO2009028158A1 (en) | 2007-08-24 | 2009-03-05 | Oncotherapy Science, Inc. | Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker |
| AR075989A1 (es) | 2009-04-10 | 2011-05-11 | Lilly Co Eli | Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria |
| EP2427490A1 (en) | 2009-05-07 | 2012-03-14 | Novartis AG | Compositions and methods of use for binding molecules to dickkopf-1 or dickkopf-4 or both |
| CA2783665A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2012103787A1 (en) * | 2011-02-01 | 2012-08-09 | The University Of Hongkong | Use of anti-dkk1 monoclonal antibody for treatment of liver cancer |
| JP6465790B2 (ja) * | 2013-02-27 | 2019-02-06 | 第一三共株式会社 | Ｍａｐｋシグナル伝達経路を阻害する化合物に対する応答性を予測する方法 |
| CA2931975A1 (en) | 2013-12-02 | 2015-06-11 | Oncomed Pharmaceuticals, Inc. | Identification of predictive biomarkers associated with wnt pathway inhibitors |
| CA3041325A1 (en) | 2016-10-26 | 2018-05-03 | Leap Therapeutics, Inc. | Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody |
| CA3151228A1 (en) | 2019-09-19 | 2021-03-25 | Leap Therapeutics, Inc. | Use of dkk-1 inhibitors for treating cancer |
| EP4061419A1 (en) | 2019-11-22 | 2022-09-28 | Leap Therapeutics, Inc. | Methods of treating cancer using dkk-1-inhibitors |
| WO2023039249A1 (en) | 2021-09-10 | 2023-03-16 | Leap Therapeutics, Inc. | Combination therapy |
| IL318268A (en) | 2022-07-12 | 2025-03-01 | Leap Therapeutics Inc | Combined treatment |
-
2017
- 2017-10-26 CA CA3041325A patent/CA3041325A1/en active Pending
- 2017-10-26 MX MX2019004940A patent/MX2019004940A/es unknown
- 2017-10-26 JP JP2019522823A patent/JP7374765B2/ja active Active
- 2017-10-26 BR BR112019008279-4A patent/BR112019008279A2/pt active Search and Examination
- 2017-10-26 WO PCT/US2017/058555 patent/WO2018081437A1/en not_active Ceased
- 2017-10-26 CN CN201780071597.0A patent/CN110114087A/zh active Pending
- 2017-10-26 KR KR1020197014600A patent/KR102701695B1/ko active Active
- 2017-10-26 IL IL266199A patent/IL266199B2/en unknown
- 2017-10-26 MA MA046673A patent/MA46673A/fr unknown
- 2017-10-26 SG SG11201903602RA patent/SG11201903602RA/en unknown
- 2017-10-26 EP EP17808633.6A patent/EP3532099A1/en active Pending
- 2017-10-26 AU AU2017347822A patent/AU2017347822B2/en active Active
- 2017-10-26 US US16/345,191 patent/US11267876B2/en active Active
- 2017-10-26 RU RU2019115946A patent/RU2019115946A/ru unknown
-
2022
- 2022-01-28 US US17/587,708 patent/US12319730B2/en active Active
-
2023
- 2023-07-26 JP JP2023121862A patent/JP2023133432A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11267876B2 (en) | 2022-03-08 |
| CA3041325A1 (en) | 2018-05-03 |
| MX2019004940A (es) | 2019-09-26 |
| SG11201903602RA (en) | 2019-05-30 |
| AU2017347822A1 (en) | 2019-05-09 |
| IL266199B1 (en) | 2024-10-01 |
| IL266199B2 (en) | 2025-02-01 |
| RU2019115946A (ru) | 2020-11-27 |
| AU2017347822B2 (en) | 2025-01-16 |
| US20190284264A1 (en) | 2019-09-19 |
| CN110114087A (zh) | 2019-08-09 |
| KR20190085935A (ko) | 2019-07-19 |
| US12319730B2 (en) | 2025-06-03 |
| KR102701695B1 (ko) | 2024-08-30 |
| US20220289831A1 (en) | 2022-09-15 |
| JP7374765B2 (ja) | 2023-11-07 |
| JP2019533693A (ja) | 2019-11-21 |
| MA46673A (fr) | 2019-09-04 |
| JP2023133432A (ja) | 2023-09-22 |
| EP3532099A1 (en) | 2019-09-04 |
| IL266199A (en) | 2019-06-30 |
| RU2019115946A3 (https=) | 2021-01-26 |
| WO2018081437A1 (en) | 2018-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019008279A2 (pt) | uso de beta-catenina como um biomarcador para tratamento de cânceres usando anticorpo anti-dkk-1 | |
| BR112019008494A2 (pt) | anticorpos para pd-1 e usos dos mesmos | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| BR112018011336A2 (pt) | anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer | |
| BR112015021979A2 (pt) | Anticorpos humanos para grem1 | |
| BR112018002274A2 (pt) | anticorpos anti-pd-1 | |
| BR112017022845A2 (pt) | neoepítopos de câncer | |
| BR112019005823A2 (pt) | tratamento para enxaqueca refratária | |
| MX2017003565A (es) | Anticuerpos anti-edad para el tratamiento de inflamacion y trastornos autoinmunes. | |
| BR112016030310A2 (pt) | Compostos de platina, composições e seus usos | |
| BR112017006825A2 (pt) | anticorpos contra receptor do fator de necrose tumoral induzido por glicocorticoides (gitr) e seus métodos de utilização | |
| BR112016014284A2 (pt) | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo | |
| BR112016030908A2 (pt) | moléculas com especificidade para cd45 e cd79 | |
| BR112016020752A2 (pt) | ?anticorpo isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, e, métodos para tratamento de um câncer ou tumor expressando egfrviii e para tratamento de um câncer, redução de crescimento de tumor e/ou causação de regressão de tumor em um paciente? | |
| BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
| BR112017011235A2 (pt) | anticorpos anti-c5 e métodos de uso | |
| BR112017008914A2 (pt) | método para tratar câncer, composição e uso da composição | |
| BR112016026993A2 (pt) | combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer | |
| BR112017000671A2 (pt) | moléculas com especificidade para cd79 e cd22 | |
| BR112015023262A2 (pt) | anticorpo isolado, ácido nucleico isolado, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica e usos do anticorpo | |
| BR112016011401A2 (pt) | moduladores de aplnr e utilizações dos mesmos | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112015030356A2 (pt) | métodos de tratamento de uma taupatia | |
| BR112016004324A2 (pt) | anticorpos | |
| BR112018072066A2 (pt) | moléculas de ligação específicas para fcgamariia e uso das mesmas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] |